Imperial Innovations Group plc (AIM: IVO, "Innovations" or "the Group"), a leading technology commercialisation and investment group, has published its results for the year ended 31 July 2015.
Martin Knight, Chairman of Imperial Innovations, said:
"We have had another year of good progress, producing a healthy profit and delivering on our promise to increase substantially our rate of investment. In fact we have almost doubled it, investing £60.8 million across 30 companies.
"A key highlight of the year, was the transformation of Circassia into a FTSE 250 specialty biopharmaceutical company, following its completion of two acquisitions and £275.0 million placing. The successful nurturing of Circassia from an original £2.0 million seed funding round in 2007, provides an excellent illustration of our ability to build substantial, high quality businesses in which we retain a meaningful stake.
"The business model is proven beyond doubt. We have created a strong platform, based on access to the UK's finest science-driven intellectual property, a highly professional investment capability and an executive team with a deep understanding of both the academic mind set and know-how to commercialise early-stage technology.
"We also have a strong balance sheet and the support of an impressive group of like-minded shareholders and co-investors.
"All the key ingredients are in place for us to back our winners, particularly as there are a significant number of companies in our portfolio with the potential to replicate Circassia's success."
A pdf copy of the results is available at http://www.imperialinnovations.co.uk
Issued for and on behalf of Imperial Innovations by Instinctif Partners.
For more information please contact: email@example.com